nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—DDC—respiratory system—lung cancer	0.00454	0.149	CbGeAlD
Methyldopa—COMT—respiratory system—lung cancer	0.003	0.0986	CbGeAlD
Methyldopa—SLC15A1—epithelium—lung cancer	0.00282	0.0926	CbGeAlD
Methyldopa—COMT—bronchus—lung cancer	0.00247	0.0811	CbGeAlD
Methyldopa—DDC—lung—lung cancer	0.00241	0.0791	CbGeAlD
Methyldopa—COMT—trachea—lung cancer	0.00222	0.0728	CbGeAlD
Methyldopa—COMT—cardiac atrium—lung cancer	0.00209	0.0684	CbGeAlD
Methyldopa—COMT—bone marrow—lung cancer	0.00176	0.0578	CbGeAlD
Methyldopa—DDC—lymph node—lung cancer	0.00165	0.0541	CbGeAlD
Methyldopa—COMT—lung—lung cancer	0.00159	0.0523	CbGeAlD
Methyldopa—ADRA2A—bronchus—lung cancer	0.00126	0.0413	CbGeAlD
Methyldopa—ADRA2A—trachea—lung cancer	0.00113	0.0371	CbGeAlD
Methyldopa—COMT—lymph node—lung cancer	0.00109	0.0358	CbGeAlD
Methyldopa—ADRA2A—cardiac atrium—lung cancer	0.00106	0.0348	CbGeAlD
Methyldopa—Hypersensitivity—Topotecan—lung cancer	0.000897	0.00138	CcSEcCtD
Methyldopa—Angiopathy—Paclitaxel—lung cancer	0.000894	0.00138	CcSEcCtD
Methyldopa—Constipation—Vinorelbine—lung cancer	0.00089	0.00137	CcSEcCtD
Methyldopa—Mediastinal disorder—Paclitaxel—lung cancer	0.000888	0.00137	CcSEcCtD
Methyldopa—Hepatobiliary disease—Docetaxel—lung cancer	0.00088	0.00136	CcSEcCtD
Methyldopa—Asthenia—Topotecan—lung cancer	0.000873	0.00135	CcSEcCtD
Methyldopa—Myalgia—Gemcitabine—lung cancer	0.000872	0.00134	CcSEcCtD
Methyldopa—Arthralgia—Gemcitabine—lung cancer	0.000872	0.00134	CcSEcCtD
Methyldopa—Agranulocytosis—Docetaxel—lung cancer	0.000868	0.00134	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.000866	0.00134	CcSEcCtD
Methyldopa—Asthenia—Erlotinib—lung cancer	0.000864	0.00133	CcSEcCtD
Methyldopa—Mental disorder—Paclitaxel—lung cancer	0.000863	0.00133	CcSEcCtD
Methyldopa—Oedema—Irinotecan—lung cancer	0.000859	0.00132	CcSEcCtD
Methyldopa—Diarrhoea—Vinblastine—lung cancer	0.000857	0.00132	CcSEcCtD
Methyldopa—Leukopenia—Cisplatin—lung cancer	0.000855	0.00132	CcSEcCtD
Methyldopa—Infection—Irinotecan—lung cancer	0.000853	0.00131	CcSEcCtD
Methyldopa—Flatulence—Paclitaxel—lung cancer	0.000845	0.0013	CcSEcCtD
Methyldopa—Nervous system disorder—Irinotecan—lung cancer	0.000842	0.0013	CcSEcCtD
Methyldopa—Thrombocytopenia—Irinotecan—lung cancer	0.000841	0.0013	CcSEcCtD
Methyldopa—Eczema—Doxorubicin—lung cancer	0.000839	0.00129	CcSEcCtD
Methyldopa—Oedema—Gemcitabine—lung cancer	0.000836	0.00129	CcSEcCtD
Methyldopa—Hepatitis—Docetaxel—lung cancer	0.000835	0.00129	CcSEcCtD
Methyldopa—Diarrhoea—Topotecan—lung cancer	0.000833	0.00128	CcSEcCtD
Methyldopa—Cardiac failure congestive—Doxorubicin—lung cancer	0.000831	0.00128	CcSEcCtD
Methyldopa—Infection—Gemcitabine—lung cancer	0.000831	0.00128	CcSEcCtD
Methyldopa—Dizziness—Vinblastine—lung cancer	0.000828	0.00128	CcSEcCtD
Methyldopa—Diarrhoea—Erlotinib—lung cancer	0.000824	0.00127	CcSEcCtD
Methyldopa—Body temperature increased—Vinorelbine—lung cancer	0.000823	0.00127	CcSEcCtD
Methyldopa—Connective tissue disorder—Docetaxel—lung cancer	0.000821	0.00127	CcSEcCtD
Methyldopa—Nervous system disorder—Gemcitabine—lung cancer	0.00082	0.00126	CcSEcCtD
Methyldopa—Thrombocytopenia—Gemcitabine—lung cancer	0.000819	0.00126	CcSEcCtD
Methyldopa—Myalgia—Cisplatin—lung cancer	0.000813	0.00125	CcSEcCtD
Methyldopa—Skin disorder—Gemcitabine—lung cancer	0.000812	0.00125	CcSEcCtD
Methyldopa—ADRA2A—lung—lung cancer	0.000812	0.0266	CbGeAlD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000808	0.00124	CcSEcCtD
Methyldopa—Dizziness—Topotecan—lung cancer	0.000805	0.00124	CcSEcCtD
Methyldopa—Liver function test abnormal—Methotrexate—lung cancer	0.000803	0.00124	CcSEcCtD
Methyldopa—Vomiting—Vinblastine—lung cancer	0.000796	0.00123	CcSEcCtD
Methyldopa—Dizziness—Erlotinib—lung cancer	0.000796	0.00123	CcSEcCtD
Methyldopa—Breast disorder—Methotrexate—lung cancer	0.000786	0.00121	CcSEcCtD
Methyldopa—Headache—Vinblastine—lung cancer	0.000785	0.00121	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Methotrexate—lung cancer	0.000784	0.00121	CcSEcCtD
Methyldopa—Leukopenia—Etoposide—lung cancer	0.000783	0.00121	CcSEcCtD
Methyldopa—Oedema—Cisplatin—lung cancer	0.000779	0.0012	CcSEcCtD
Methyldopa—Cardiac disorder—Docetaxel—lung cancer	0.000775	0.00119	CcSEcCtD
Methyldopa—Infection—Cisplatin—lung cancer	0.000774	0.00119	CcSEcCtD
Methyldopa—Vomiting—Topotecan—lung cancer	0.000774	0.00119	CcSEcCtD
Methyldopa—Paraesthesia—Irinotecan—lung cancer	0.000771	0.00119	CcSEcCtD
Methyldopa—Leukopenia—Paclitaxel—lung cancer	0.000768	0.00118	CcSEcCtD
Methyldopa—Rash—Topotecan—lung cancer	0.000767	0.00118	CcSEcCtD
Methyldopa—Hypersensitivity—Vinorelbine—lung cancer	0.000767	0.00118	CcSEcCtD
Methyldopa—Dermatitis—Topotecan—lung cancer	0.000767	0.00118	CcSEcCtD
Methyldopa—Vomiting—Erlotinib—lung cancer	0.000765	0.00118	CcSEcCtD
Methyldopa—Nervous system disorder—Cisplatin—lung cancer	0.000764	0.00118	CcSEcCtD
Methyldopa—Thrombocytopenia—Cisplatin—lung cancer	0.000763	0.00118	CcSEcCtD
Methyldopa—Headache—Topotecan—lung cancer	0.000762	0.00117	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000762	0.00117	CcSEcCtD
Methyldopa—Rash—Erlotinib—lung cancer	0.000759	0.00117	CcSEcCtD
Methyldopa—Dermatitis—Erlotinib—lung cancer	0.000758	0.00117	CcSEcCtD
Methyldopa—Angiopathy—Docetaxel—lung cancer	0.000758	0.00117	CcSEcCtD
Methyldopa—Skin disorder—Cisplatin—lung cancer	0.000757	0.00117	CcSEcCtD
Methyldopa—Headache—Erlotinib—lung cancer	0.000754	0.00116	CcSEcCtD
Methyldopa—Mediastinal disorder—Docetaxel—lung cancer	0.000753	0.00116	CcSEcCtD
Methyldopa—Paraesthesia—Gemcitabine—lung cancer	0.000751	0.00116	CcSEcCtD
Methyldopa—Asthenia—Vinorelbine—lung cancer	0.000747	0.00115	CcSEcCtD
Methyldopa—Eosinophilia—Methotrexate—lung cancer	0.000745	0.00115	CcSEcCtD
Methyldopa—Nausea—Vinblastine—lung cancer	0.000744	0.00115	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Irinotecan—lung cancer	0.000741	0.00114	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.00074	0.00114	CcSEcCtD
Methyldopa—Pancreatitis—Methotrexate—lung cancer	0.000737	0.00114	CcSEcCtD
Methyldopa—Constipation—Irinotecan—lung cancer	0.000734	0.00113	CcSEcCtD
Methyldopa—Mental disorder—Docetaxel—lung cancer	0.000732	0.00113	CcSEcCtD
Methyldopa—Myalgia—Paclitaxel—lung cancer	0.00073	0.00113	CcSEcCtD
Methyldopa—Arthralgia—Paclitaxel—lung cancer	0.00073	0.00113	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000725	0.00112	CcSEcCtD
Methyldopa—Nausea—Topotecan—lung cancer	0.000723	0.00111	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000722	0.00111	CcSEcCtD
Methyldopa—Constipation—Gemcitabine—lung cancer	0.000715	0.0011	CcSEcCtD
Methyldopa—Nausea—Erlotinib—lung cancer	0.000715	0.0011	CcSEcCtD
Methyldopa—Pancytopenia—Methotrexate—lung cancer	0.000714	0.0011	CcSEcCtD
Methyldopa—Diarrhoea—Vinorelbine—lung cancer	0.000712	0.0011	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Cisplatin—lung cancer	0.00071	0.00109	CcSEcCtD
Methyldopa—Infection—Etoposide—lung cancer	0.000709	0.00109	CcSEcCtD
Methyldopa—Oedema—Paclitaxel—lung cancer	0.0007	0.00108	CcSEcCtD
Methyldopa—Paraesthesia—Cisplatin—lung cancer	0.0007	0.00108	CcSEcCtD
Methyldopa—Thrombocytopenia—Etoposide—lung cancer	0.000699	0.00108	CcSEcCtD
Methyldopa—Liver function test abnormal—Doxorubicin—lung cancer	0.000696	0.00107	CcSEcCtD
Methyldopa—Infection—Paclitaxel—lung cancer	0.000696	0.00107	CcSEcCtD
Methyldopa—Skin disorder—Etoposide—lung cancer	0.000694	0.00107	CcSEcCtD
Methyldopa—Erectile dysfunction—Methotrexate—lung cancer	0.000693	0.00107	CcSEcCtD
Methyldopa—Dizziness—Vinorelbine—lung cancer	0.000688	0.00106	CcSEcCtD
Methyldopa—Orthostatic hypotension—Doxorubicin—lung cancer	0.000688	0.00106	CcSEcCtD
Methyldopa—Nervous system disorder—Paclitaxel—lung cancer	0.000687	0.00106	CcSEcCtD
Methyldopa—Thrombocytopenia—Paclitaxel—lung cancer	0.000686	0.00106	CcSEcCtD
Methyldopa—Breast disorder—Doxorubicin—lung cancer	0.000681	0.00105	CcSEcCtD
Methyldopa—Skin disorder—Paclitaxel—lung cancer	0.00068	0.00105	CcSEcCtD
Methyldopa—Body temperature increased—Irinotecan—lung cancer	0.000679	0.00105	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Doxorubicin—lung cancer	0.000679	0.00105	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Cisplatin—lung cancer	0.000673	0.00104	CcSEcCtD
Methyldopa—Infestation NOS—Methotrexate—lung cancer	0.000671	0.00103	CcSEcCtD
Methyldopa—Infestation—Methotrexate—lung cancer	0.000671	0.00103	CcSEcCtD
Methyldopa—Vomiting—Vinorelbine—lung cancer	0.000662	0.00102	CcSEcCtD
Methyldopa—Body temperature increased—Gemcitabine—lung cancer	0.000661	0.00102	CcSEcCtD
Methyldopa—Rash—Vinorelbine—lung cancer	0.000656	0.00101	CcSEcCtD
Methyldopa—Dermatitis—Vinorelbine—lung cancer	0.000656	0.00101	CcSEcCtD
Methyldopa—Abdominal distension—Doxorubicin—lung cancer	0.000656	0.00101	CcSEcCtD
Methyldopa—Headache—Vinorelbine—lung cancer	0.000652	0.00101	CcSEcCtD
Methyldopa—Leukopenia—Docetaxel—lung cancer	0.000651	0.001	CcSEcCtD
Methyldopa—Eosinophilia—Doxorubicin—lung cancer	0.000645	0.000994	CcSEcCtD
Methyldopa—Paraesthesia—Etoposide—lung cancer	0.000641	0.000988	CcSEcCtD
Methyldopa—Pancreatitis—Doxorubicin—lung cancer	0.000639	0.000984	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000638	0.000983	CcSEcCtD
Methyldopa—Angina pectoris—Doxorubicin—lung cancer	0.000634	0.000978	CcSEcCtD
Methyldopa—Hepatobiliary disease—Methotrexate—lung cancer	0.000634	0.000978	CcSEcCtD
Methyldopa—Hypersensitivity—Irinotecan—lung cancer	0.000633	0.000975	CcSEcCtD
Methyldopa—Paraesthesia—Paclitaxel—lung cancer	0.000629	0.000969	CcSEcCtD
Methyldopa—Agranulocytosis—Methotrexate—lung cancer	0.000626	0.000965	CcSEcCtD
Methyldopa—Myalgia—Docetaxel—lung cancer	0.000619	0.000954	CcSEcCtD
Methyldopa—Arthralgia—Docetaxel—lung cancer	0.000619	0.000954	CcSEcCtD
Methyldopa—Pancytopenia—Doxorubicin—lung cancer	0.000619	0.000953	CcSEcCtD
Methyldopa—Nausea—Vinorelbine—lung cancer	0.000618	0.000953	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Etoposide—lung cancer	0.000617	0.00095	CcSEcCtD
Methyldopa—Body temperature increased—Cisplatin—lung cancer	0.000616	0.00095	CcSEcCtD
Methyldopa—Asthenia—Irinotecan—lung cancer	0.000616	0.000949	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000615	0.000948	CcSEcCtD
Methyldopa—Constipation—Etoposide—lung cancer	0.000611	0.000941	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000604	0.000932	CcSEcCtD
Methyldopa—Hepatitis—Methotrexate—lung cancer	0.000602	0.000928	CcSEcCtD
Methyldopa—Asthenia—Gemcitabine—lung cancer	0.0006	0.000925	CcSEcCtD
Methyldopa—Constipation—Paclitaxel—lung cancer	0.000599	0.000923	CcSEcCtD
Methyldopa—Oedema—Docetaxel—lung cancer	0.000593	0.000915	CcSEcCtD
Methyldopa—Weight increased—Doxorubicin—lung cancer	0.000593	0.000914	CcSEcCtD
Methyldopa—Infection—Docetaxel—lung cancer	0.00059	0.000909	CcSEcCtD
Methyldopa—Diarrhoea—Irinotecan—lung cancer	0.000587	0.000905	CcSEcCtD
Methyldopa—Nervous system disorder—Docetaxel—lung cancer	0.000582	0.000897	CcSEcCtD
Methyldopa—Thrombocytopenia—Docetaxel—lung cancer	0.000581	0.000896	CcSEcCtD
Methyldopa—Infestation NOS—Doxorubicin—lung cancer	0.000581	0.000895	CcSEcCtD
Methyldopa—Infestation—Doxorubicin—lung cancer	0.000581	0.000895	CcSEcCtD
Methyldopa—Skin disorder—Docetaxel—lung cancer	0.000576	0.000888	CcSEcCtD
Methyldopa—Hypersensitivity—Cisplatin—lung cancer	0.000574	0.000885	CcSEcCtD
Methyldopa—Diarrhoea—Gemcitabine—lung cancer	0.000572	0.000882	CcSEcCtD
Methyldopa—Dizziness—Irinotecan—lung cancer	0.000568	0.000875	CcSEcCtD
Methyldopa—Jaundice—Doxorubicin—lung cancer	0.000566	0.000872	CcSEcCtD
Methyldopa—Body temperature increased—Etoposide—lung cancer	0.000565	0.00087	CcSEcCtD
Methyldopa—Aminosalicylic Acid—PTGS2—lung cancer	0.000561	0.378	CrCbGaD
Methyldopa—Asthenia—Cisplatin—lung cancer	0.000559	0.000862	CcSEcCtD
Methyldopa—Cardiac disorder—Methotrexate—lung cancer	0.000559	0.000861	CcSEcCtD
Methyldopa—ADRA2A—lymph node—lung cancer	0.000555	0.0182	CbGeAlD
Methyldopa—Body temperature increased—Paclitaxel—lung cancer	0.000554	0.000853	CcSEcCtD
Methyldopa—Hepatobiliary disease—Doxorubicin—lung cancer	0.000549	0.000847	CcSEcCtD
Methyldopa—Angiopathy—Methotrexate—lung cancer	0.000546	0.000842	CcSEcCtD
Methyldopa—Vomiting—Irinotecan—lung cancer	0.000546	0.000841	CcSEcCtD
Methyldopa—Mediastinal disorder—Methotrexate—lung cancer	0.000543	0.000836	CcSEcCtD
Methyldopa—Agranulocytosis—Doxorubicin—lung cancer	0.000542	0.000835	CcSEcCtD
Methyldopa—Rash—Irinotecan—lung cancer	0.000541	0.000834	CcSEcCtD
Methyldopa—Dermatitis—Irinotecan—lung cancer	0.000541	0.000834	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000541	0.000833	CcSEcCtD
Methyldopa—Headache—Irinotecan—lung cancer	0.000538	0.000829	CcSEcCtD
Methyldopa—Diarrhoea—Cisplatin—lung cancer	0.000533	0.000822	CcSEcCtD
Methyldopa—Paraesthesia—Docetaxel—lung cancer	0.000533	0.000821	CcSEcCtD
Methyldopa—Vomiting—Gemcitabine—lung cancer	0.000532	0.00082	CcSEcCtD
Methyldopa—Bradycardia—Doxorubicin—lung cancer	0.000531	0.000818	CcSEcCtD
Methyldopa—Mental disorder—Methotrexate—lung cancer	0.000527	0.000813	CcSEcCtD
Methyldopa—Rash—Gemcitabine—lung cancer	0.000527	0.000813	CcSEcCtD
Methyldopa—Dermatitis—Gemcitabine—lung cancer	0.000527	0.000812	CcSEcCtD
Methyldopa—Hypersensitivity—Etoposide—lung cancer	0.000526	0.000811	CcSEcCtD
Methyldopa—Headache—Gemcitabine—lung cancer	0.000524	0.000807	CcSEcCtD
Methyldopa—Hepatitis—Doxorubicin—lung cancer	0.000521	0.000804	CcSEcCtD
Methyldopa—Hypersensitivity—Paclitaxel—lung cancer	0.000516	0.000795	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Docetaxel—lung cancer	0.000512	0.00079	CcSEcCtD
Methyldopa—Asthenia—Etoposide—lung cancer	0.000512	0.00079	CcSEcCtD
Methyldopa—Connective tissue disorder—Doxorubicin—lung cancer	0.000512	0.00079	CcSEcCtD
Methyldopa—Nausea—Irinotecan—lung cancer	0.00051	0.000786	CcSEcCtD
Methyldopa—Constipation—Docetaxel—lung cancer	0.000508	0.000782	CcSEcCtD
Methyldopa—Asthenia—Paclitaxel—lung cancer	0.000502	0.000774	CcSEcCtD
Methyldopa—Nausea—Gemcitabine—lung cancer	0.000497	0.000766	CcSEcCtD
Methyldopa—Vomiting—Cisplatin—lung cancer	0.000496	0.000764	CcSEcCtD
Methyldopa—Rash—Cisplatin—lung cancer	0.000491	0.000758	CcSEcCtD
Methyldopa—Dermatitis—Cisplatin—lung cancer	0.000491	0.000757	CcSEcCtD
Methyldopa—Diarrhoea—Etoposide—lung cancer	0.000489	0.000753	CcSEcCtD
Methyldopa—Cardiac disorder—Doxorubicin—lung cancer	0.000484	0.000746	CcSEcCtD
Methyldopa—Isoprenaline—CYP1A1—lung cancer	0.000482	0.325	CrCbGaD
Methyldopa—Diarrhoea—Paclitaxel—lung cancer	0.000479	0.000738	CcSEcCtD
Methyldopa—Angiopathy—Doxorubicin—lung cancer	0.000473	0.000729	CcSEcCtD
Methyldopa—Dizziness—Etoposide—lung cancer	0.000472	0.000728	CcSEcCtD
Methyldopa—Mediastinal disorder—Doxorubicin—lung cancer	0.00047	0.000724	CcSEcCtD
Methyldopa—Body temperature increased—Docetaxel—lung cancer	0.000469	0.000723	CcSEcCtD
Methyldopa—Leukopenia—Methotrexate—lung cancer	0.000469	0.000723	CcSEcCtD
Methyldopa—Dizziness—Paclitaxel—lung cancer	0.000463	0.000714	CcSEcCtD
Methyldopa—Nausea—Cisplatin—lung cancer	0.000463	0.000714	CcSEcCtD
Methyldopa—Mental disorder—Doxorubicin—lung cancer	0.000457	0.000704	CcSEcCtD
Methyldopa—Vomiting—Etoposide—lung cancer	0.000454	0.0007	CcSEcCtD
Methyldopa—Rash—Etoposide—lung cancer	0.00045	0.000694	CcSEcCtD
Methyldopa—Dermatitis—Etoposide—lung cancer	0.00045	0.000693	CcSEcCtD
Methyldopa—Headache—Etoposide—lung cancer	0.000447	0.00069	CcSEcCtD
Methyldopa—Flatulence—Doxorubicin—lung cancer	0.000447	0.000689	CcSEcCtD
Methyldopa—Arthralgia—Methotrexate—lung cancer	0.000446	0.000688	CcSEcCtD
Methyldopa—Myalgia—Methotrexate—lung cancer	0.000446	0.000688	CcSEcCtD
Methyldopa—Vomiting—Paclitaxel—lung cancer	0.000445	0.000686	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000443	0.000683	CcSEcCtD
Methyldopa—Rash—Paclitaxel—lung cancer	0.000441	0.00068	CcSEcCtD
Methyldopa—Dermatitis—Paclitaxel—lung cancer	0.000441	0.00068	CcSEcCtD
Methyldopa—Mesalazine—PTGS2—lung cancer	0.00044	0.297	CrCbGaD
Methyldopa—Headache—Paclitaxel—lung cancer	0.000439	0.000676	CcSEcCtD
Methyldopa—Hypersensitivity—Docetaxel—lung cancer	0.000437	0.000674	CcSEcCtD
Methyldopa—Asthenia—Docetaxel—lung cancer	0.000426	0.000656	CcSEcCtD
Methyldopa—Infection—Methotrexate—lung cancer	0.000425	0.000655	CcSEcCtD
Methyldopa—Nausea—Etoposide—lung cancer	0.000424	0.000654	CcSEcCtD
Methyldopa—Nervous system disorder—Methotrexate—lung cancer	0.000419	0.000647	CcSEcCtD
Methyldopa—Thrombocytopenia—Methotrexate—lung cancer	0.000419	0.000645	CcSEcCtD
Methyldopa—Nausea—Paclitaxel—lung cancer	0.000416	0.000641	CcSEcCtD
Methyldopa—Skin disorder—Methotrexate—lung cancer	0.000415	0.00064	CcSEcCtD
Methyldopa—Leukopenia—Doxorubicin—lung cancer	0.000406	0.000626	CcSEcCtD
Methyldopa—Diarrhoea—Docetaxel—lung cancer	0.000406	0.000626	CcSEcCtD
Methyldopa—Dizziness—Docetaxel—lung cancer	0.000392	0.000605	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Methotrexate—lung cancer	0.00039	0.000601	CcSEcCtD
Methyldopa—Arthralgia—Doxorubicin—lung cancer	0.000386	0.000595	CcSEcCtD
Methyldopa—Myalgia—Doxorubicin—lung cancer	0.000386	0.000595	CcSEcCtD
Methyldopa—Paraesthesia—Methotrexate—lung cancer	0.000384	0.000592	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000384	0.000591	CcSEcCtD
Methyldopa—Vomiting—Docetaxel—lung cancer	0.000377	0.000582	CcSEcCtD
Methyldopa—Rash—Docetaxel—lung cancer	0.000374	0.000577	CcSEcCtD
Methyldopa—Dermatitis—Docetaxel—lung cancer	0.000374	0.000576	CcSEcCtD
Methyldopa—Headache—Docetaxel—lung cancer	0.000372	0.000573	CcSEcCtD
Methyldopa—Oedema—Doxorubicin—lung cancer	0.00037	0.000571	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Methotrexate—lung cancer	0.000369	0.000569	CcSEcCtD
Methyldopa—Infection—Doxorubicin—lung cancer	0.000368	0.000567	CcSEcCtD
Methyldopa—Nervous system disorder—Doxorubicin—lung cancer	0.000363	0.00056	CcSEcCtD
Methyldopa—Thrombocytopenia—Doxorubicin—lung cancer	0.000363	0.000559	CcSEcCtD
Methyldopa—Skin disorder—Doxorubicin—lung cancer	0.00036	0.000554	CcSEcCtD
Methyldopa—Nausea—Docetaxel—lung cancer	0.000353	0.000543	CcSEcCtD
Methyldopa—Body temperature increased—Methotrexate—lung cancer	0.000338	0.000521	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000337	0.00052	CcSEcCtD
Methyldopa—Paraesthesia—Doxorubicin—lung cancer	0.000333	0.000513	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Doxorubicin—lung cancer	0.00032	0.000493	CcSEcCtD
Methyldopa—Constipation—Doxorubicin—lung cancer	0.000317	0.000488	CcSEcCtD
Methyldopa—Hypersensitivity—Methotrexate—lung cancer	0.000315	0.000486	CcSEcCtD
Methyldopa—Asthenia—Methotrexate—lung cancer	0.000307	0.000473	CcSEcCtD
Methyldopa—Body temperature increased—Doxorubicin—lung cancer	0.000293	0.000451	CcSEcCtD
Methyldopa—Diarrhoea—Methotrexate—lung cancer	0.000293	0.000451	CcSEcCtD
Methyldopa—Dizziness—Methotrexate—lung cancer	0.000283	0.000436	CcSEcCtD
Methyldopa—Hypersensitivity—Doxorubicin—lung cancer	0.000273	0.000421	CcSEcCtD
Methyldopa—Vomiting—Methotrexate—lung cancer	0.000272	0.000419	CcSEcCtD
Methyldopa—Rash—Methotrexate—lung cancer	0.00027	0.000416	CcSEcCtD
Methyldopa—Dermatitis—Methotrexate—lung cancer	0.000269	0.000415	CcSEcCtD
Methyldopa—Headache—Methotrexate—lung cancer	0.000268	0.000413	CcSEcCtD
Methyldopa—Asthenia—Doxorubicin—lung cancer	0.000266	0.00041	CcSEcCtD
Methyldopa—Nausea—Methotrexate—lung cancer	0.000254	0.000392	CcSEcCtD
Methyldopa—Diarrhoea—Doxorubicin—lung cancer	0.000253	0.000391	CcSEcCtD
Methyldopa—Dizziness—Doxorubicin—lung cancer	0.000245	0.000377	CcSEcCtD
Methyldopa—Vomiting—Doxorubicin—lung cancer	0.000235	0.000363	CcSEcCtD
Methyldopa—Rash—Doxorubicin—lung cancer	0.000234	0.00036	CcSEcCtD
Methyldopa—Dermatitis—Doxorubicin—lung cancer	0.000233	0.00036	CcSEcCtD
Methyldopa—Headache—Doxorubicin—lung cancer	0.000232	0.000358	CcSEcCtD
Methyldopa—Nausea—Doxorubicin—lung cancer	0.00022	0.000339	CcSEcCtD
Methyldopa—ADRA2A—Signaling by GPCR—GRM8—lung cancer	0.000178	0.000556	CbGpPWpGaD
Methyldopa—DDC—Metabolism—STK11—lung cancer	0.000176	0.00055	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP2E1—lung cancer	0.000175	0.000548	CbGpPWpGaD
Methyldopa—COMT—Metabolism—NQO1—lung cancer	0.000173	0.000542	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—POMC—lung cancer	0.00017	0.000531	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—HRAS—lung cancer	0.000169	0.000529	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CKB—lung cancer	0.000166	0.000519	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CD—lung cancer	0.000165	0.000515	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AXL—lung cancer	0.000163	0.00051	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTP1—lung cancer	0.000162	0.000509	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—ALB—lung cancer	0.000162	0.000509	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GRP—lung cancer	0.000161	0.000504	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—OXTR—lung cancer	0.000161	0.000504	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—CREBBP—lung cancer	0.000158	0.000496	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CAT—lung cancer	0.000158	0.000495	CbGpPWpGaD
Methyldopa—COMT—Metabolism—STK11—lung cancer	0.000156	0.000488	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTM2—lung cancer	0.000156	0.000488	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CNDP2—lung cancer	0.000156	0.000488	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—AVP—lung cancer	0.000155	0.000484	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ABCB1—lung cancer	0.000154	0.000482	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MTMR3—lung cancer	0.000151	0.000474	CbGpPWpGaD
Methyldopa—DDC—Metabolism—TYMS—lung cancer	0.000151	0.000473	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GNG11—lung cancer	0.000151	0.000472	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTM1—lung cancer	0.000149	0.000468	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ALB—lung cancer	0.000148	0.000464	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PGAM1—lung cancer	0.000148	0.000462	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—RAF1—lung cancer	0.000147	0.00046	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GRP—lung cancer	0.000146	0.000458	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—OXTR—lung cancer	0.000146	0.000458	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTP1—lung cancer	0.000144	0.000452	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CB—lung cancer	0.000143	0.000449	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ITGB1—lung cancer	0.000142	0.000445	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYP1A1—lung cancer	0.000142	0.000443	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP2A7—lung cancer	0.000141	0.000441	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CAT—lung cancer	0.00014	0.00044	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ERCC2—lung cancer	0.00014	0.00044	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SDC4—lung cancer	0.000138	0.000431	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GNG11—lung cancer	0.000137	0.000429	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ABCB1—lung cancer	0.000137	0.000428	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—ADCY1—lung cancer	0.000136	0.000425	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—lung cancer	0.000135	0.000422	CbGpPWpGaD
Methyldopa—COMT—Metabolism—TYMS—lung cancer	0.000134	0.00042	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—RAF1—lung cancer	0.000134	0.00042	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTM1—lung cancer	0.000133	0.000415	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—IL2—lung cancer	0.000132	0.000413	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CXCL8—lung cancer	0.000131	0.000411	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—COL4A2—lung cancer	0.000127	0.000397	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PTHLH—lung cancer	0.000126	0.000395	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP1A1—lung cancer	0.000126	0.000394	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—RRM1—lung cancer	0.000125	0.000393	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTA3—lung cancer	0.000125	0.000393	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ERCC2—lung cancer	0.000125	0.00039	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GIPR—lung cancer	0.000123	0.000386	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ADCY1—lung cancer	0.000123	0.000386	CbGpPWpGaD
Methyldopa—DDC—Metabolism—APOA1—lung cancer	0.000121	0.00038	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PPP2R1B—lung cancer	0.00012	0.000376	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—ANXA1—lung cancer	0.000118	0.000371	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—B4GALT5—lung cancer	0.000118	0.000369	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SDC4—lung cancer	0.000115	0.000361	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—SRC—lung cancer	0.000115	0.00036	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTA4—lung cancer	0.000115	0.000359	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTHLH—lung cancer	0.000114	0.000358	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DUSP3—lung cancer	0.000113	0.000353	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—APP—lung cancer	0.000112	0.000352	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—lung cancer	0.000112	0.000351	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTA2—lung cancer	0.000112	0.00035	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CG—lung cancer	0.000111	0.000347	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RHEB—lung cancer	0.000111	0.000347	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MMP1—lung cancer	0.00011	0.000346	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTA1—lung cancer	0.000108	0.000338	CbGpPWpGaD
Methyldopa—COMT—Metabolism—APOA1—lung cancer	0.000108	0.000338	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ANXA1—lung cancer	0.000108	0.000337	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCC3—lung cancer	0.000107	0.000334	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—MAPK3—lung cancer	0.000106	0.000332	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—APOA1—lung cancer	0.000106	0.000331	CbGpPWpGaD
Methyldopa—DDC—Metabolism—POMC—lung cancer	0.000106	0.000331	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GRM8—lung cancer	0.000105	0.000329	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	0.000104	0.000327	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKR1C1—lung cancer	0.000103	0.000324	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CREBBP—lung cancer	0.000103	0.000322	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—POMC—lung cancer	0.000103	0.000322	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—APP—lung cancer	0.000102	0.000319	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SKI—lung cancer	0.000102	0.000318	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—UGT1A1—lung cancer	0.0001	0.000314	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CG—lung cancer	9.84e-05	0.000308	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CD—lung cancer	9.75e-05	0.000305	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GNG11—lung cancer	9.67e-05	0.000303	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CG—lung cancer	9.65e-05	0.000302	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ALB—lung cancer	9.62e-05	0.000301	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—EGF—lung cancer	9.54e-05	0.000299	CbGpPWpGaD
Methyldopa—COMT—Metabolism—POMC—lung cancer	9.37e-05	0.000293	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALDOA—lung cancer	9.21e-05	0.000288	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CREBBP—lung cancer	9.13e-05	0.000286	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CREBBP—lung cancer	8.95e-05	0.00028	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NCOA3—lung cancer	8.94e-05	0.00028	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PXN—lung cancer	8.82e-05	0.000276	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—lung cancer	8.74e-05	0.000274	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AVP—lung cancer	8.73e-05	0.000274	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCG2—lung cancer	8.7e-05	0.000272	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ADCY1—lung cancer	8.7e-05	0.000272	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CD—lung cancer	8.65e-05	0.000271	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GRP—lung cancer	8.64e-05	0.000271	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKR1C1—lung cancer	8.64e-05	0.000271	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—OXTR—lung cancer	8.64e-05	0.000271	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALB—lung cancer	8.54e-05	0.000268	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ENO2—lung cancer	8.53e-05	0.000267	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HPGDS—lung cancer	8.53e-05	0.000267	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CB—lung cancer	8.49e-05	0.000266	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CD—lung cancer	8.48e-05	0.000266	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPP2R1B—lung cancer	8.47e-05	0.000265	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—lung cancer	8.42e-05	0.000264	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ALB—lung cancer	8.37e-05	0.000262	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTT1—lung cancer	8.27e-05	0.000259	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GCLC—lung cancer	8.18e-05	0.000256	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP2A6—lung cancer	8.18e-05	0.000256	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GNG11—lung cancer	8.09e-05	0.000253	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCL8—lung cancer	7.94e-05	0.000249	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AVP—lung cancer	7.93e-05	0.000248	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ENO1—lung cancer	7.75e-05	0.000243	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFC—lung cancer	7.7e-05	0.000241	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—RAF1—lung cancer	7.57e-05	0.000237	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CB—lung cancer	7.54e-05	0.000236	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—lung cancer	7.47e-05	0.000234	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CB—lung cancer	7.39e-05	0.000232	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTEN—lung cancer	7.34e-05	0.00023	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADCY1—lung cancer	7.27e-05	0.000228	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—AKT1—lung cancer	7.14e-05	0.000224	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PPP2R1B—lung cancer	7.09e-05	0.000222	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SMARCA4—lung cancer	7.09e-05	0.000222	CbGpPWpGaD
Methyldopa—DDC—Metabolism—EP300—lung cancer	7e-05	0.000219	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP2E1—lung cancer	6.95e-05	0.000218	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NQO1—lung cancer	6.87e-05	0.000215	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HSPB1—lung cancer	6.84e-05	0.000214	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IL2—lung cancer	6.79e-05	0.000213	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTHLH—lung cancer	6.76e-05	0.000212	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTEN—lung cancer	6.52e-05	0.000204	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ANXA1—lung cancer	6.36e-05	0.000199	CbGpPWpGaD
Methyldopa—COMT—Metabolism—EP300—lung cancer	6.22e-05	0.000195	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—STK11—lung cancer	6.2e-05	0.000194	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FLT1—lung cancer	6.15e-05	0.000193	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CG—lung cancer	6.1e-05	0.000191	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—EP300—lung cancer	6.09e-05	0.000191	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APP—lung cancer	6.02e-05	0.000189	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH3—lung cancer	6.02e-05	0.000189	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGF9—lung cancer	5.98e-05	0.000187	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SRC—lung cancer	5.92e-05	0.000186	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—POMC—lung cancer	5.8e-05	0.000182	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—lung cancer	5.77e-05	0.000181	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTP1—lung cancer	5.73e-05	0.00018	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JUNB—lung cancer	5.71e-05	0.000179	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NRAS—lung cancer	5.7e-05	0.000179	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CAT—lung cancer	5.58e-05	0.000175	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CG—lung cancer	5.54e-05	0.000173	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MAPK3—lung cancer	5.46e-05	0.000171	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCB1—lung cancer	5.43e-05	0.00017	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CD—lung cancer	5.36e-05	0.000168	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TYMS—lung cancer	5.33e-05	0.000167	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—POMC—lung cancer	5.27e-05	0.000165	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTM1—lung cancer	5.27e-05	0.000165	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STK11—lung cancer	5.18e-05	0.000162	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CA—lung cancer	5.18e-05	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6R—lung cancer	5.14e-05	0.000161	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FOXO3—lung cancer	5e-05	0.000157	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP1A1—lung cancer	4.99e-05	0.000156	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ERCC2—lung cancer	4.95e-05	0.000155	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—KRAS—lung cancer	4.91e-05	0.000154	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAP2K1—lung cancer	4.9e-05	0.000153	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CD—lung cancer	4.87e-05	0.000152	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AVP—lung cancer	4.69e-05	0.000147	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CB—lung cancer	4.67e-05	0.000146	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CA—lung cancer	4.6e-05	0.000144	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF1R—lung cancer	4.51e-05	0.000141	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CA—lung cancer	4.51e-05	0.000141	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL8—lung cancer	4.49e-05	0.000141	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HES1—lung cancer	4.43e-05	0.000139	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—lung cancer	4.36e-05	0.000137	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—RAF1—lung cancer	4.35e-05	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—IL2—lung cancer	4.29e-05	0.000134	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOA1—lung cancer	4.28e-05	0.000134	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CB—lung cancer	4.24e-05	0.000133	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AKT1—lung cancer	4.23e-05	0.000133	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—HRAS—lung cancer	4.17e-05	0.000131	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL8—lung cancer	4.08e-05	0.000128	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB3—lung cancer	4.05e-05	0.000127	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CG—lung cancer	3.91e-05	0.000123	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL2—lung cancer	3.9e-05	0.000122	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TERT—lung cancer	3.88e-05	0.000122	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGFR1—lung cancer	3.77e-05	0.000118	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AKT1—lung cancer	3.76e-05	0.000118	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—POMC—lung cancer	3.72e-05	0.000117	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HIF1A—lung cancer	3.71e-05	0.000116	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT1—lung cancer	3.68e-05	0.000115	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CREBBP—lung cancer	3.63e-05	0.000114	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOA1—lung cancer	3.58e-05	0.000112	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KDR—lung cancer	3.55e-05	0.000111	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CD—lung cancer	3.44e-05	0.000108	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALB—lung cancer	3.39e-05	0.000106	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KIT—lung cancer	3.27e-05	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APC—lung cancer	3.27e-05	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CG—lung cancer	3.27e-05	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—NRAS—lung cancer	3.27e-05	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGF—lung cancer	3.23e-05	0.000101	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAPK3—lung cancer	3.13e-05	9.81e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—POMC—lung cancer	3.11e-05	9.75e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BRAF—lung cancer	3.07e-05	9.63e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6R—lung cancer	3.04e-05	9.51e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CREBBP—lung cancer	3.03e-05	9.5e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CB—lung cancer	3e-05	9.39e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EGFR—lung cancer	2.98e-05	9.34e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—lung cancer	2.97e-05	9.3e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAP2K1—lung cancer	2.89e-05	9.07e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CD—lung cancer	2.88e-05	9.01e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CA—lung cancer	2.85e-05	8.92e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—KRAS—lung cancer	2.82e-05	8.82e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTEN—lung cancer	2.59e-05	8.11e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	2.59e-05	8.1e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MDM2—lung cancer	2.58e-05	8.07e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RAF1—lung cancer	2.57e-05	8.04e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB2—lung cancer	2.54e-05	7.96e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	2.51e-05	7.85e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MTOR—lung cancer	2.51e-05	7.85e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—EP300—lung cancer	2.47e-05	7.74e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL8—lung cancer	2.41e-05	7.54e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HRAS—lung cancer	2.39e-05	7.5e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	2.33e-05	7.29e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASP3—lung cancer	2.31e-05	7.22e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL2—lung cancer	2.3e-05	7.21e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6—lung cancer	2.29e-05	7.17e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCND1—lung cancer	2.24e-05	7.03e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JUN—lung cancer	2.24e-05	7.01e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—lung cancer	2.18e-05	6.82e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	2.17e-05	6.8e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTEN—lung cancer	2.17e-05	6.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT1—lung cancer	2.11e-05	6.62e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EP300—lung cancer	2.07e-05	6.47e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SRC—lung cancer	2.01e-05	6.29e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—lung cancer	1.96e-05	6.13e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT3—lung cancer	1.94e-05	6.07e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NRAS—lung cancer	1.93e-05	6.05e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK3—lung cancer	1.85e-05	5.8e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CA—lung cancer	1.83e-05	5.72e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—lung cancer	1.8e-05	5.64e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGFR—lung cancer	1.76e-05	5.51e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KRAS—lung cancer	1.66e-05	5.21e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	1.53e-05	4.79e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKT1—lung cancer	1.49e-05	4.68e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—lung cancer	1.48e-05	4.63e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HRAS—lung cancer	1.41e-05	4.43e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6—lung cancer	1.35e-05	4.24e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT1—lung cancer	1.25e-05	3.91e-05	CbGpPWpGaD
